Metabolic (Dysfunction)-Associated Fatty Liver Disease in Chinese Patients with Type 2 Diabetes from a Subcenter of the National Metabolic Management Center
Table 2
Clinical characteristics in different MAFLD categories stratified by BMI.
Clinical characteristics
MAFLD ()
Lean ()
Nonobese ()
Obese ()
Participants
519 (23.1)
1702 (75.7)
545 (24.3)
Male
298 (57.4)
1102 (64.7)†
395 (72.5)
Age (years)
†
Diabetes duration (years)
5.3 (0.8, 10.7)
5.6 (0.9, 11.0)†
3.3 (0.1, 9.2)
BMI (kg/m2)
†
PLT (109/L)
AST (U/L)
19 (16, 24)
20 (16, 26)†
23 (18, 31)
ALT (U/L)
20 (15, 29)
22 (16, 32)†
29 (20, 43)
ALB (g/dL)
Fasting glucose (mmol/L)
Fasting insulin (μIU/mL)
6.70 (4.41, 9.56)
7.77 (5.41, 10.72)†
10.80 (7.49, 14.51)
Postprandial glucose (mmol/L)
†
Postprandial insulin (μIU/mL)
23.89 (14.92, 40.73)
26.85 (16.96, 43.32)†
33.26 (19.94, 55.58)
TC (mmol/L)
TG (mmol/L)
1.73 (1.23, 2.57)
1.79 (1.30, 2.61)†
1.96 (1.43, 3.05)
HDL (mmol/L)
LDL (mmol/L)
HbA1c (%)
HOMA-IR
2.51 (1.69, 4.00)
3.00 (2.01, 4.48)†
4.30 (2.86, 6.08)
TyG index
†
Smoking
221 (27.8)
569 (28.8)
167 (30.6)
Drinking
51 (6.4)
143 (7.2)
38 (7.0)
Hypertension history
167 (32.2)
665 (39.1)†
273 (50.1)
Dyslipidemia history
207 (39.9)
753 (44.2)†
287 (52.7)
Data are expressed as , median (25th percentile, 75th percentile), or (%). MAFLD: metabolic (dysfunction)-associated fatty liver disease; BMI: body mass index; PLT: platelet; AST: aspartic acid aminotransferase; ALT: alanine aminotransferase; ALB: albumin; TC: total cholesterol; TG: triacylglycerols; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; HbA1c: glycated hemoglobin; HOMA-IR: homeostasis model assessment for insulin resistance; TyG: triglyceride-glucose index. and † indicated for comparisons lean versus obese and nonobese versus obese MAFLD.
